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Abstract
Background: The excretion of amino acids in urine represents an important avenue for the loss of key nutrients.
Some amino acids such as glycine and histidine are lost in higher abundance than others. These two amino acids
perform important physiological functions and are required for the synthesis of key proteins such as haemoglobin
and collagen.
Methods: Stage 1 of this study involved healthy subjects (n = 151) who provided first of the morning urine samples
and completed symptom questionnaires. Urine was analysed for amino acid composition by gas chromatography.
Stage 2 involved a subset of the initial cohort (n = 37) who completed a 30 day trial of an amino acid supplement
and subsequent symptom profile evaluation.
Results: Analyses of urinary amino acid profiles revealed that three groups could be objectively defined from the
151 participants using k-means clustering. The amino acid profiles were significantly different between each of the
clusters (Wilks’ Lambda = 0.13, p < 0.0001). Cluster 1 had the highest loss of amino acids with histidine being the
most abundant component. Cluster 2 had glycine present as the most abundant urinary amino acid and cluster 3
had equivalent abundances of glycine and histidine. Strong associations were observed between urinary proline
concentrations and fatigue/pain scores (r = .56 to .83) for females in cluster 1, with several other differential sets of
associations observed for the other clusters.
Conclusions: Different phenotypic subsets exist in the population based on amino acid excretion characteristics
found in urine. Provision of the supplement resulted in significant improvements in reported fatigue and sleep for
81% of the trial cohort with all females reporting improvements in fatigue.
Trial registration: The study was registered on the 18th April 2011 with the Australian New Zealand Clinical Trials
Registry (ACTRN12611000403932).
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Background
The amino acids derived from ingested proteins are used
as substrates for the biosynthesis of structural and func-
tional proteins in the body. These digested amino acids
can be used for oxidative phosphorylation and gluconeo-
genesis [1, 2] as well as the facilitation of numerous
physiological functions including acting as precursors
for the biosynthesis of neurotransmitters [3], hormones,
phosphoglycerols, glycolipids and nucleic acids [4, 5]. It
has been estimated that the skeletal muscles in the hu-
man body comprise 40–60% of body mass and thus rep-
resent the major repository of the body’s protein [6].
The body does not maintain specific protein stores, but
when it is not possible to obtain sufficient protein via in-
gestion during exercise, ill health or trauma, the body
accesses amino acids via the process of proteolysis where
the non-myofibrillar proteins display a high turnover rate
to meet demands [7]. The amino acids released from this
turnover of protein can enter the blood circulation for
metabolism as required and can also be lost in sweat and
urine [1, 2]. Healthy resting human adults can achieve ni-
trogen balance by taking in around 0.8 g/Kg/day of pro-
tein [6]; humans synthesise approximately 3 g/Kg/day of
new protein [8], indicating that reutilisation of amino
acids released during protein turnover is critical to health.
High levels of exercise activity would increase the re-
quirement for protein intake and for protein turnover in
order to offset the increased losses of free amino acids aris-
ing from demands for energy metabolism, tissue repair and
recovery processes [8, 9] as well as excretory losses via
sweating [10, 11]. Similar increased demands for amino
acids would be seen during illness and recovery from
trauma. Increased losses of amino acids were observed in
breast cancer patients who suffered fatigue during and fol-
lowing radiation therapy, with evidence for altered amino
acid homeostasis [12]. Significantly depleted amino acid
levels have also been associated with long-term fatigue [13]
leading to the proposal that the nitrogen balance in these
patients was less than optimal. A negative nitrogen balance
may arise if the supply of amino acids is inadequate as a re-
sult of insufficient protein ingestion or impaired digestion
such that the body’s requirements for protein synthesis
cannot be met. The demand for amino acids is met via pro-
teolysis of non-myofibrillar muscle proteins. A prolonged
state of negative nitrogen balance could result in proteoly-
sis of myofibrillar proteins which would in turn lead to
muscle wasting and damage. Increased metabolic activities
to support exercise, mount host defences against infection,
or support recovery from illness and injury, place additional
demands on protein turnover within the body [6–8].
It has been shown that the levels of several key amino
acids including serine, glycine, histidine, alanine and orni-
thine are present in sweat at much higher concentrations
than occur in the plasma [10, 11, 14, 15]. It was proposed
that these levels of amino acids in sweat, as has been
found to be the case with sweat electrolytes [16], could be
achieved by a process of leaching of the amino acids from
the natural moisturising factor in the stratum corneum of
the skin to combine with the quantities excreted in sweat
[10, 11, 15]. The majority of amino acids which constitute
the natural moisturising factor are thought to be derived
from the protein filaggrin which is primarily composed of
glutamine/glutamic acid, arginine/ornithine, serine, pro-
line, glycine, histidine, and aspartic acid/alanine [17]. Loss
of amino acids via sweating as a result of exercise, living in
a hot climate, or night sweats associated with illness could
exacerbate the requirement for proteolysis when the body
cannot obtain proteins via ingestion. It is proposed that
subjects experiencing a net negative nitrogen balance with
depleted amino acid resources would experience fatigue
and pain [1, 18, 19]. If a net negative nitrogen balance is
associated with fatigue then it would follow that amino
acid supplementation would have the potential to assist in
restoring nitrogen balance. Provision of free amino acids
removes the requirement for digestion of proteins; amino
acids can be directly absorbed into the circulation making
them rapidly available to the body’s tissues and organs in-
cluding striated muscle. The development of an amino
acid supplement is not straightforward as considerations
of solubility, palatability, composition and dosage need to
be addressed [20]. A pilot study on healthy male subjects
from the general population experiencing non-debilitating
fatigue, demonstrated that a 30 day period of daily supple-
mentation with a complex formulation of amino acids re-
sulted in significantly improved scores for fatigue as well
as associated alterations in urinary excretion of amino
acids [21].
An early study from our laboratory revealed that amino
acid excretion profiles could delineate human subjects suf-
fering fatigue into population subgroups [22]. The basis
for differentiation was thought to involve genetic differ-
ences in kidney reabsorption mechanisms, metabolic effi-
ciencies, skin moisturisation and sweating processes as
well as environmental factors such as dietary influences
and infective history. The proposal that different human
phenotypes exist on the basis of amino acid homeostasis
may explain why some subjects are more susceptible to
developing chronic fatigue or are better able to cope with
different types of exercise challenge. Fatigue illness is
highly prevalent in Western society and significant fatigue
is a common feature of many medical conditions [23].
Sub-health is a state that falls between health and disease
and involves psychological, physical and medical compo-
nents believed to increase the risk of illness [24].
Methods
The current study aimed to determine whether healthy
individuals could be separated into discrete subgroups
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based on the makeup of their urinary excretion profiles.
Analyses of a broad range of symptoms were assessed to
build a symptom index evaluation of general fatigue,
general body pains, gastrointestinal function, sleep and
vitality for evaluating sub-health in the general healthy
population. Following the initial recruitment and urine
analysis, healthy subjects that reported non-debilitating
levels of fatigue were provided with a complex amino
acid supplement to assess whether supplementation for
30 days would alleviate fatigue. Memberships of popula-
tion subgroups based on amino acid excretion profiles
were tested to determine whether subgroup membership
influenced the efficacy of the supplement.
The study involved recruiting healthy adults who were
reportedly free from any significant medical or psycho-
logical condition. The project was divided into two stages;
172 subjects were initially recruited to supply urine sam-
ples for analyses and complete general health and fatigue
questionnaires as summarised in Fig. 1. Recruits were not
included if they did not provide urinary samples or they
did not complete the questionnaires for evaluation of gen-
eral health symptoms and fatigue. The standardised tim-
ing of the urine sample collection was aimed at assessing
the profile composition of amino acids representing
homeostasis without contributions of the dietary intake
associated with the 24 h collection of urine [25]. Partici-
pants therefore provided a fasted first of the morning
urine sample which was transported in a Urine-
Monovette® 10 ml boric acid tube (Sarstedt, Germany).
Amino acid analysis of the urine samples was performed
using the commercial EZ: Faast™ derivatisation method
(esterification of amino acids) followed by gas chromatog-
raphy/flame ionisation detection (GC/FID) as previously
described [25].
The Chalder fatigue scale questionnaire (total 11 items,
seven items related to physical symptoms of fatigue and
four items related to mental symptoms of fatigue, Likert
scored) was used to assess levels of fatigue; the scale has
been validated for use in both a healthy population free
from any known medical conditions as well as patients
with various forms of chronic fatigue [26]. The current
general health of the participants was also assessed using
an 86 item questionnaire which was based on a question-
naire previously used by our research team [27–29] which
included symptoms covering fatigue, pain, gastrointestinal
(GIT), cognitive, neurological and infection related symp-
toms. Participants were required to report how much they
had been affected by these symptoms during the previous
7 days. The questionnaire was Likert scored with responses
ranging from 0 “not at all” to 4 “extremely”. Five symptom
indices were compiled from symptoms pertaining to the
categories of general fatigue, general body pain, GIT func-
tion, sleep and vitality in order to evaluate the potential in-
fluence of supplementation on general health as shown in
Table 1. General body pain and GIT symptoms were moni-
tored to determine whether any adverse side effects were
associated with the amino acid supplement. Correlation
and factor analyses were carried out to select the minimum
number of optimal symptoms required to define each
symptom index and to remove any redundant items.
Eligible subjects were enrolled in stage 2 (n = 73) of
the program to receive the Fatigue Reviva™ amino acid
Fig. 1 Study design including statistical analyses for the amino acid supplement trial
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supplement for a 30 day period. Participants were re-
quired to take 20 g of the amino acid based dietary sup-
plement dissolved in 100 ml of water daily. The
commercially available nutritional supplement, Fatigue
RevivaTM (Top Nutrition Pty Ltd) was comprised of
20 L-amino acids (glycine, proline, glutamine, carnitine,
threonine, lysine, alanine, valine, taurine, serine, cysteine,
arginine, histidine, isoleucine, phenylalanine, leucine, me-
thionine, glutamic acid, aspartic acid, tyrosine), fructo-
oligosaccharide (FOS), malic acid, citric acid, succinic acid,
ribose, 13 minerals and 13 vitamins. Production of the
supplement Fatigue RevivaTM was carried out according
to the restrictions of the NSW Food Regulation 2010 [30],
the NSW Food Act 2003 [31] and the Foods Standards
Code (FSANZ) [32] whilst the dosages were governed by
restrictions of the NSW Food Authority.
At the end of the 30 days, participant data were ex-
cluded from the analyses if they had either not taken the
supplement for a minimum of 25 days, reported having
developed an infection or did not provide a urine sample
and completed questionnaires. The data generated from
the remaining subjects’ urine samples and questionnaires
were included in the analyses. The study was carried out
as part of an initial phase of product assessment to de-
termine whether population subgroups exist and if so,
does membership of a subgroup influence the efficacy of
the supplement. The determination of population sub-
groups was deemed critical in preparation for future
studies in terms of integrating placebo treatments. Par-
ticipants were also asked to indicate whether they felt
the supplement improved their health and whether they
would continue to take the supplement if given the op-
portunity. All participants provided written consent. The
trial was registered with the Australian New Zealand
Clinical Trials Registry (ACTRN12611000403932) and
approved by the University of Newcastle Human Re-
search Ethics Committee (H-2010-1313).
Chalder fatigue scale scores were analysed using Wil-
coxon signed-rank test. The general health questionnaire
data were assessed by correlation and factor analyses to
construct symptom indices appropriate for assessing the
impact of amino acid supplementation on general health
and wellbeing. Amino acid data were assessed for nor-
mality using Shapiro-Wilks W test. Univariate analysis
of amino acid data included ANOVA, Wilcoxon
matched pairs test and Mann-Whitney U test. Multivari-
ate analysis of amino acid data included standard and
forward stepwise function analysis of arcsine trans-
formed data. Comparisons were made between the
amino acid profiles, general health and levels of fatigue
pre- and post-supplementation for a cohort of partici-
pants (n = 37) who had both successfully completed the
amino acid trial and for whom both pre-supplement and
post-supplement urine samples were assessed for amino
acid content. K-means cluster analysis was used to sep-
arate the data collected pre-supplement from 151 partic-
ipants into three groups based upon their amino acid
profiles (relative abundance data). Comparisons were
then made between the amino acid profiles pre- and post-
supplementation of the three sub-groups based upon the
results of the cluster analysis. Statistical analyses were car-
ried out using Dell Statistica (data analysis software sys-
tem), version 13, software.dell.com, Dell Inc. (2015).
Levels of statistical significance were set at p < 0.05.
Results
Initial evaluation of urinary excretion patterns
Initially, 172 participants (aged 18 years or older) were
recruited from the general public for stage 1 of the
study. A final study group of 151 subjects provided urine
samples and full responses to questionnaires and were
reportedly free from any significant medical conditions.
The participant group comprised 99 males with an aver-
age age of 29.5 ± 11.8 (mean ± SD) and 52 females with
an average age of 35 ± 13.7. The first stage of the investi-
gation involved appraising the pre-supplementation
urine excretion profiles of the 151 recruits. The amino
acid compositions were determined by GC-FID analyses
and used to generate a dataset of relative percentage
abundances of 29 amino acids and amino acid deriva-
tives. These data were assessed by k-means clustering
techniques to determine that the study participants
Table 1 Symptom indices based on selected items from an 86-item general health questionnaire
General Fatigue Index Pain Index Gastrointestinal Index Sleep Index Vitality Index
Individual scale items
Low in energy Muscle cramps Abdominal pain Prolonged Sleep Libido
Trouble concentrating Face pain Diarrhoea Trouble falling asleep Night sweats
Muscle weakness Neck Pain Constipation Trouble awakening Cravings
Forgetfulness Shoulder pain Irritable bowel Disturbed sleep
Everything an effort Arm pain Gastric reflux Mental fatigue
Mental confusion Muscle soreness
Heavy limbs
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could be partitioned into three clusters based the amino
acid relative abundances with a minimum cluster mem-
bership of n > 10. Standard discriminant function ana-
lysis was then applied to determine whether each of the
clusters had significantly different amino acid profiles
(Wilks’ Lambda = 0.13, F(46,252) = 9.85, p < 0.0001) as
shown in the canonical plot (Fig. 2) with glycine and his-
tidine levels providing the major discrimination between
the groups. The members in each cluster were tightly
grouped based upon their urinary excretion profiles and
each subgroup was clearly resolved from the other sub-
groups with minimal overlap.
Seventeen amino acids contributed towards differenti-
ating the composition profiles of the clusters by display-
ing significant differences in relative abundances for the
subgroups and the concentrations of the key compo-
nents have been summarised in Table 2. Histidine and
glycine were the most abundant amino acids in the urin-
ary profiles and displayed different relative abundances
for each of the three clusters. Cluster 1 was charac-
terised by a high histidine to glycine ratio of 2.0, cluster
2 displayed a low ratio of 0.4 and cluster 3 had equiva-
lent levels resulting in a ratio of 1.0. Cluster 1 had the
highest total urinary concentration of excreted amino
acids where histidine levels were 2.4 – 3.6 times those in
clusters 3 and 2 respectively. Cluster 1 also had signifi-
cantly higher concentrations of glutamine, tyrosine and
the branch chain amino acids compared with both clus-
ters 2 and 3. In addition, serine and alanine were higher
in cluster 1 compared with cluster 3 (Table 2). Cluster 2
was equivalent to cluster 3 in these parameters but was
clearly distinguished by the high level of glycine excre-
tion in the urine.
The objective partitioning by k-means clustering of
subjects based on similarities in their urinary excretion
profile removed user-bias in group allocation. Cluster 3
had the highest frequency of membership (46%) followed
by cluster 1 (32%) and then cluster 2 (22%) as shown in
Table 2. The three subgroups within the study cohort
had similar BMI values and were primarily Caucasian.
Clusters 1 and 3 had similar mean ages but cluster 2 had
a significantly higher mean age than both clusters 1 and
3. Gender was not equally balanced across the three
groups where cluster 2 contained predominantly females
(p < 0.05). Sixteen out of 27 males who identified them-
selves as athletes were assigned to cluster 1, ten to cluster
3 and only one to cluster 2. There were no significant dif-
ferences in total amino acid concentrations between the
genders in the whole study cohort where males (n = 99)
had a mean level of 5185 ± 290 μmol/L (mean ± SEM) and
females (n = 52) 4955 ± 452 μmol/L. Comparisons be-
tween the urinary compositions of amino acids in males
and females revealed significant differences for glutamic
acid (males 16.7 ± 2 vs females 25.0 ± 3 μmol/L, p < 0.05),
glycine-proline dipeptide (78.0 ± 5 vs 54.7 ± 6 μmol/L, p <
0.01), proline-hydroxyproline dipeptide (234.3 ± 15 vs
154.7 ± 19 μmol/L, p < 0.01) and tyrosine (96.8 ± 7 vs 72.8
± 9 μmol/L, p < 0.05).
Levels of fatigue were assessed using the Chalder fa-
tigue scale [26] where the average total fatigue score was
calculated to be 13.6 ± 5.9 (mean ± SD) for the whole
group. However, evaluation of the clusters revealed that
cluster 2 had a significantly higher level of total fatigue
compared with cluster 1, while clusters 1 and 3 had
similar scores (Table 2). The results of the Chalder fa-
tigue scale were mirrored by the fatigue index results de-
rived from the general health questionnaire. Cluster 2
also reported higher levels of symptoms assessed by the
sleep index compared with cluster 1.
Correlation analyses were performed to evaluate po-
tential associations between the levels of urinary metab-
olites and the various symptom indices for each of the
clusters. There were distinctive arrays of correlations
noted for each of the clusters with some strong positive
associations (r > .50) noted for cluster 1 females (Table 3).
It was evident for females belonging to cluster 1 (n = 13)
that higher urinary concentrations of glutamic acid,
hydroxylysine, methionine, ornithine, proline and valine
were all positively correlated with values of the Chalder
physical fatigue score (r > .55, p < 0.05). In the same group,
increasing scores in the gastrointestinal index were very
strongly associated with higher urinary levels of pro-
line (r = .92), methionine (r = .82) and valine (r = .70).
These amino acids were also correlated with a range of
other symptoms as shown in Table 3. Females in Cluster 2
only exhibited positive correlations for two amino acids,
where the urinary concentration for asparagine was asso-
ciated with the gastrointestinal index and proline was
associated with all four fatigue measures and the gastro-





















Fig. 2 Discriminant function canonical plot of subgroups generated
via k-means clustering
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negative associations between general fatigue and alanine,
aspartic acid, isoleucine, phenylalanine, and tyrosine. The
males in cluster 1 displayed nine negative correlations be-
tween amino acids and symptoms, where seven of these
involved associations with the gastrointestinal index
(Table 4). The males from cluster 2 had positive associa-
tions between α-aminobutyric acid and the four fatigue in-
dices. The males from cluster 3 had six symptom indices
(all four fatigue measures, pain and vitality) positively as-
sociated with β-aminoisobutyric acid and showed no
negative correlations.
Evaluation of amino acid supplementation
Compliance for the supplementation trial was 51% where
37 participants successfully completed the trial by taking
the amino acid supplement for a period of 25–30 days as
well as returning general health questionnaires and pro-
viding post-supplement urine samples. The supplement
trial cohort (n = 37) comprised 10 females and had an
average age of 33.8 years ranging from 19 to 65 years.
Levels of fatigue were assessed using both the Chalder
fatigue scale [26] and a general fatigue index developed
by the current research team, where lower scores were
indicative of a lower level of fatigue for both measures.
After completion of the supplement trial, 30 out of the
group of 37 participants (81%) reported an improve-
ment in their levels of fatigue. A significant reduction
in the mean total fatigue scores for the entire cohort
was observed from 13.4 ± 0.8 (mean ± SEM) to 8.8 ±
0.6 (Wilcoxon matched pairs test, p < 0.0001) follow-
ing supplementation. General health and wellbeing
was also assessed using an 86 item questionnaire from
which several indices were generated (Table 1). Scores
were standardised to values out of 40, where a score of “0”
indicated that the subject was not affected by any of the
symptoms comprising that index, and a score of “40” indi-
cating that the subject experienced all of the symptoms in
the index group to a high degree. Following supplementa-
tion, significant reductions in questionnaire scores repre-
senting potential improvements were seen in the fatigue,
Table 2 Characteristics of participant groups by amino acid profile cluster: significant differences in amino acid levels and symptom
indices








Mean Agea 26.0 (1.2) 37.8 (2.3) 31.9 (1.6) C1 < C2 = C3 p < 0.001
Mean BMIa 24.8 (0.4) 24.2 (0.7) 25.4 (0.4) ns
Proportion Males (number)a 75% (36) 30.3% (10) 75.7% (53) C2 < C1 = C3 p < 0.001
Caucasian (%)a 95.1% 100% 93.8% ns
Urine Amino Acids
Total amino acids μmole/L 6,609 (495) 4,339 (462) 4,425 (306) C1 > C2 = C3 p < 0.01‡
Histidine 2,152 (185) 599 (76) 886 (74) C1 > C2 = C3 p < 0.0001
Glycine 1,077 (86) 1,412 (157) 861 (68) C2 > C3 p < 0.001
Glutamine 626 (63) 443 (46) 480 (29) C1 > C2 = C3 p < 0.05
Serine 411 (49) 320 (34) 279 (16) C1 > C3 p < 0.05
Alanine 313 (29) 232 (25) 236 (18) C1 > C3 p < 0.05
Tyrosine 129 (13) 57 (8) 77 (5) C1 > C2 = C3 p < 0.0001
Branched chain amino acids 106 (7) 62 (7) 84 (6) C1 > C2 = C3 p < 0.001
Proline 5.0 (1.9) 9.1 (2.0) 10.7 (1.5) ns
Symptom Indices
Chalder total fatigue 12.8 (0.7) 16.0 (1.0) 13.4 (0.8) C2 > C1 p < 0.05
Chalder mental fatigue 4.5 (0.3) 5.9 (0.4) 4.6 (0.3) C2 > C1 = C3 p < 0.05
General fatigue index 3.2 (1.0) 11.2 (1.6) 8.3 (1.1) C2 > C1 p < 0.05
Pain index 5.1 (0.8) 8.1 (1.3) 5.3 (0.7) ns
Gastrointestinal index 1.7 (0.7) 3.8 (1.0) 2.0 (0.4) ns
Sleep index 8.2 (1.0) 14.0 (1.9) 11.5 (1.2) C2 > C1 p < 0.05
Vitality index 6.5 (1.2) 9.1 (1.3) 5.5 (0.8) ns
Statistical tests: ANOVA, Tukey’s HSD for unequal sample sizes, *Chi square; mean (SEM)
Dunstan et al. Nutrition Journal  (2017) 16:19 Page 6 of 11
sleep and vitality indices (Table 5). In response to the
questions regarding their experience using the supple-
ment, 25 responders (68%) indicated that they felt the sup-
plement had improved their health and 28 (76%) stated
that they would continue to take the supplement if given
the opportunity.
The seven participants who did not report any improve-
ments in fatigue were all males and had an average
Chalder total fatigue score of 10.0 ± 1.4 (mean ± SEM)
prior to supplementation whereas the remainder of the
cohort (n = 30) had a significantly higher mean Chalder fa-
tigue score of 14.2 ± 0.8 (Mann-Whitney U test, p < 0.02).
The participants that showed improvements in fatigue
thus had a higher level of fatigue prior to commencing the
supplementation. The larger group who reported having
Table 3 Correlations between urinary concentrations of amino
acids and symptom index scores for each of the three clusters
defined by k-means clustering of urinary amino acid profiles for
the female participants
Females:







ALA vs General fatigue ns ns r = -.56
ASN vs GIT ns r = 0.50 ns
ASP vs General fatigue ns ns r = -.50
GLU vs Chalder total fatigue r = .59 ns ns
GLU vs Chalder physical fatigue r = .63 ns ns
HYL vs Chalder physical fatigue r = .57 ns ns
HYP vs Pain r = .56 ns ns
ILE vs General fatigue ns ns r = -.49
MET vs Pain r = .66 ns ns
MET vs GIT r = .82 ns ns
MET vs Sleep r = .59 ns ns
MET vs Chalder physical fatigue r = .60 ns ns
ORN vs GIT r = .66 ns ns
ORN vs Vitality r = .58 ns ns
ORN vs Chalder total fatigue r = .59 ns ns
ORN vs Chalder physical fatigue r = .56 ns ns
PHE vs General fatigue ns ns r = -.50
PRO vs General fatigue r = .63 r = .48 ns
PRO vs Pain r = .83 ns ns
PRO vs GIT r = .92 r = .45 ns
PRO vs Sleep r = .70 ns ns
PRO vs Vitality r = .74 ns ns
PRO vs Chalder total fatigue r = .56 r = .52 ns
PRO vs Chalder physical fatigue r = .63 r = .49 ns
PRO vs Chalder mental fatigue ns r = .44 ns
TYR vs General fatigue ns ns r = -.49
VAL vs Pain r = .60 ns ns
VAL vs GIT r = .70 ns ns
VAL vs Sleep r = .61 ns ns
VAL vs Chalder total fatigue r = .60 ns ns
VAL vs Chalder physical fatigue r = .67 ns ns
Total BCAA vs Chalder physical fatigue r = .59 ns ns
Table 4 Correlations between urinary concentrations of amino
acids and symptom index scores for each of the three clusters
defined by k-means clustering of urinary amino acid profiles for
the male participants
Males:







ALA vs GIT r = -.34 ns ns
ABA vs General fatigue ns r = .47 ns
ABA vs Chalder total fatigue ns r = .56 ns
ABA vs Chalder physical fatigue ns r = .46 ns
ABA vs Chalder mental fatigue ns r = .60 ns
BAIB vs General fatigue ns ns r = .50
BAIB vs Pain ns ns r = .37
BAIB vs Vitality ns ns r = .38
BAIB vs Total fatigue ns ns r = .32
BAIB vs Chalder physical fatigue ns ns r = .28
BAIB vs Chalder mental fatigue ns ns r = .33
ASN vs General fatigue r = .34 ns ns
GLY vs GIT r = -.41 ns ns
HYP vs Vitality ns ns r = .37
LEU vs GIT r = -.49 ns ns
ORN vs Chalder mental fatigue ns ns r = .33
PHE vs GIT r = -.40 ns ns
PHE vs Chalder physical fatigue r = .35 ns ns
PHP vs Vitality r = -.37 ns ns
PHP vs Chalder physical fatigue r = -.38 ns ns
TYR vs Chalder physical fatigue r = .38 ns ns
VAL vs GIT r = -.39 ns ns
Total BCAA vs GIT r = -.47 ns ns
Total AA vs GIT r = -.36 ns ns
Table 5 Reported improvements in general health indices


















General Fatigue index 6.9 (1.2) 3.7 (1.0) <0.01
Pain index 4.7 (1.1) 3.9 (1.0) ns
Gastrointestinal index 2.0 (0.6) 2.7 (0.8) ns
Sleep index 10.4 (1.5) 6.6 (1.0) <0.01
Vitality index 6.5 (1.2) 2.2 (0.7) <0.001
Statistical test: Wilcoxon matched pairs test
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experienced relief from fatigue ultimately reported post-
supplementation fatigue scores that were significantly
lower (8.1 ± 0.6, mean ± SEM) than those who did not re-
port improved fatigue (11.7 ± 1.4, p < 0.04). Six out of the
seven males who did not respond to the amino acid sup-
plementation were classified by their pre-supplementation
urinary profile as belonging to cluster 3 and the seventh
non-responder was assigned to cluster 1.
Discussion
Analyses of the urine samples collected from the pre-
supplement cohort of 151 healthy participants revealed
that it was possible to delineate three clear clusters
based upon urinary amino acid profiles. Cluster 3 was
the most prevalent of the clusters with its membership
totalling 46% of the total cohort with the next largest,
cluster 1, comprising 32% of the cohort. An earlier study
appraised the amino acid composition of 1993 patient
urine samples referred by general practitioners to gener-
ate 6 subgroups with a minimum membership of n > 50
[22]. It was thus argued that evidence from this study of
the healthy general population and the earlier study of
referral patients [22] supported the hypothesis that
within the Australian context, phenotypic subgroups
exist within the general population based on amino acid
excretion characteristics found in urine. It is very likely
that with more subjects, a greater number of proportion-
ally smaller subgroups would emerge using k-means
clustering techniques. The additional clusters may be
relevant to certain lower frequency population pheno-
types which could be associated with congenital meta-
bolic anomalies or predispositions to certain medical
conditions. Phenotypic membership may also represent
epigenetic outcomes where responses by the body to en-
vironmental conditions (nutrition, exercise, temperature)
or responses to pathogenic challenge which have re-
sulted in alterations in amino acid homeostasis and ni-
trogen balance.
The objective of measuring the first of the morning
fasted urine samples was to minimize confounding from
dietary intake in order to assess potential differences in
body homeostasis between individuals. Cluster 1 had the
highest average concentration of amino acids in the
fasted urine samples at approximately 1.5 times the
levels measured for clusters 2 and 3. Although total
amino acid losses were not determined from 24 h urine
samples, the higher first of the morning urinary concen-
trations suggested that this group may have a greater po-
tential to lose amino acids via urinary excretion
suggesting the operation of less efficient mechanisms for
kidney reabsorption processes. Histidine was the major
component in urine from cluster 1 at 2.4 – 3.6 times the
concentrations observed in the other clusters. Histidine
has been demonstrated to be an essential amino acid in
adults on the basis that histidine deficient diets in both
animal models and human studies have led to a negative
nitrogen balance with reduced haemoglobin and haem-
atocrit levels [33]. On provision of histidine, the subjects’
nitrogen balances were restored and haemoglobin and
haematocrit levels were returned to normal [34].
Haemoglobin protein contains 10% histidine and insuffi-
cient supply of this amino acid can lead to anaemia [34].
If a particular human phenotype was more susceptible
to histidine loss then there may be a need to compensate
for such losses via an increased intake of appropriate
protein sources or a negative nitrogen balance would
slowly develop with resultant sub-optimal haemoglobin
production and associated fatigue. In a previous study
carried out by the current research team, amino acid
levels were investigated in breast cancer radiotherapy pa-
tients who developed fatigue following radiotherapy
treatment [12]. Those women who developed significant
fatigue had higher levels of urinary histidine excretion
prior to treatment compared with those women who
remained fatigue free, while their plasma histidine levels
dropped below detectable levels following radiotherapy.
Cluster 1 from the current study also displayed elevated
output of tyrosine, serine and alanine as well as the
branch chained amino acids. The excretion of tyrosine
in the urine can be indicative of higher non-myofibrillar
protein turnover [6, 35, 36] which could further contrib-
ute towards fatigue.
Cluster 2 was characterised by glycine as the major ex-
cretory product and a predominance of females (70%).
Comparison of the male and female urinary amino acid
levels for the entire cohort did not reveal any significant
differences in the concentrations of histidine, glycine,
glutamine, serine or alanine. Glycine is a non-essential
amino acid that is primarily derived from serine and is a
vital component of human metabolism. Glycine is a
major component of collagen (33%) which is the most
abundant family of proteins in the body providing struc-
ture and form for tissues and organs. Excessive losses of
glycine may negatively impact on collagen turnover
which has been shown to be higher in females [37]. In
addition to protein synthesis it has numerous metabolic
functions such the biosynthesis of heme, creatine and
nucleic acids [38]. It also has important roles in meta-
bolic regulation, bile secretion and neurological function
[38]. As glycine is utilised in so many essential pathways
and has high demands in protein synthesis, it has often
been referred to as a “conditionally essential” amino acid
in reference to situations where de novo synthesis can
no longer meet demands [38].
A major feature of cluster 3 was a set of positive corre-
lations for the males for β-aminoisobutyric acid (BAIB)
with the symptom indices for vitality, pain and all four
fatigue measures. This non-protein amino acid exists as
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two enantiomers, one as a catabolic product of the pyr-
imidine base thymine found exclusively in urine and the
other enantiomer derived from valine is found in plasma
[39]. In certain forms of anaemia and in thalassaemia
BAIB has been shown to be excreted [40] and has also
been negatively associated with haemoglobin levels and
erythrocyte count [41]. The vitality index was comprised
of the symptoms of night sweats, libido and food crav-
ings, which were grouped together by factor analysis of
the symptom profiles. Reduced testosterone levels have
been associated with night sweats [42] as well as reduced
libido [43] and insulin resistance [44]. Changes in the vi-
tality index in the males may point to reductions in tes-
tosterone levels which have previously been associated
with fatigue, muscle weakness, reduced muscle protein
synthesis and anaemia [44].
The correlation analyses of amino acids with symptom
expression measured by the various indices revealed fur-
ther differences between the three clusters. Although the
associations between urinary amino acids and symptoms
cannot be interpreted as providing a direct cause and ef-
fect mechanism, the data suggested that increased outputs
of certain metabolites contributed towards symptom ex-
pression in sub-health. The presence or absence of corre-
lations also demonstrated differences between males and
females in each of the clusters. Proline for example dis-
played a number of very strong correlations for females in
cluster 1, to a lesser extent in cluster 2 and finally no asso-
ciations at all in cluster 3. In contrast to the females, there
were no associations with proline recorded for males re-
gardless of the cluster membership. Proline together with
alanine, glycine, glutamine and valine represented 52% of
the amino acid components in resting human plasma [15]
which indicates their importance as a circulatory reservoir
to meet the body’s demands. The positive associations of
urinary proline concentration and symptoms in females
relating to fatigue and pain may point to an increased de-
mand in females due to the turnover of non-myofibrillar
protein to maintain plasma homeostasis. Proline is the
second major component of collagen (after glycine) com-
prising around 13% of the protein with a further 9% of
collagen containing hydroxyproline. The hydroxyproline is
formed via post-translational modification of pro-collagen
where residues of proline (and lysine) are hydroxylated to
form the final collagen product. Hydroxyproline is primar-
ily found in collagen, and the appearance of it in urine can
be used as a measure of collagen turnover [45, 46]. It was
thus proposed that females from cluster 1 were suscep-
tible to experiencing higher levels of fatigue and pain if
they had higher urinary levels of the collagen components
hydroxyproline, hydroxylysine and proline. Collagen turn-
over is generally thought to be higher in females due to
the influence of oestrogen on the maintenance of joint
flexibility [47]. Chronic fatigue syndrome is reportedly
more prevalent in women [48, 49]. The same cluster 1 also
had a significantly higher urinary concentration of tyrosine
which can also be indicative of an elevated turnover of
non-myofibrillar proteins [35, 36]. Higher rates of collagen
turnover and losses of proline in urine could therefore
have significant implications for meeting the demand for
collagen synthesis in a broad range of body tissues and
organ systems.
The supplement trial was completed successfully, but
only 51% of the recruits were considered to have complied
sufficiently by completing a minimum of 25 days of sup-
plementation, completing the questionnaires and provid-
ing a final urine sample. Low compliance with trials of
this nature is recognised as a common problem [50]. The
group that completed the supplementation trial had a
similar distribution of gender and cluster membership as
observed in the first study survey. The low numbers made
it impossible to evaluate differences between the males
and females within the subgroups and so the majority of
the analyses were focussed on the whole study group with
references as appropriate to the incidence of non-
responders to the supplement in the various clusters.
The trial group reported experiencing improvements
in wellbeing following the supplementation period as ev-
idenced by reductions in the Chalder fatigue scores as
well as the general health indices for fatigue, sleep and
vitality. The Chalder fatigue scale has been validated for
use in the general population as well as those suffering
ill health [51]. In the current study, substantial reduc-
tions in fatigue were reported with 81% of the cohort in-
dicating an improvement in fatigue and all female
participants reporting an improvement in fatigue after
taking the supplement. The formulation of the amino
acid supplement was such that it would have provided a
direct source of amino acids capable of reducing the re-
quirement for non-myofibrillar catabolism and therefore
it had the potential to relieve fatigue. The higher levels
of urinary histidine (cluster 1) and glycine (cluster 2)
could have contributed to limitations in haemoglobin
production and collagen turnover respectively and
provision of both histidine and glycine in the supple-
ment may have led to enhancements in the synthesis of
these proteins [33, 34, 38, 45] and a reduction in associ-
ated symptoms such as fatigue and pain.
The seven participants who did not show any improve-
ment following supplementation were all males, six of
whom belonged to cluster 3. Cluster 3 had no obvious
anomalies of high level excretions of amino acids such as
those observed for histidine (cluster 1) and glycine (cluster
2). In addition, the males that did not respond to amino acid
support had low Chalder fatigue scores at the beginning of
the supplementation period and were therefore not experi-
encing problematic levels of fatigue in need of treatment.
Thus it was concluded that males primarily assigned to
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cluster 3 via initial urine analysis and who also had low
Chalder fatigue scores would be unlikely to achieve im-
proved levels of fatigue from supplementation with amino
acids. These subjects would appear to have been free from
the symptoms that characterise sub-health. The combined
use of the urinary amino acid profiling and the Chalder
fatigue scale could be effectively utilised in future testing of
amino acid supplementation by allowing selection of those
individuals most likely to be experiencing a negative
nitrogen balance and fatigue, and who would therefore
potentially be more likely to benefit from amino acid
support. The use of the general health questionnaire indices
provided a framework for appraising the symptoms of sub-
health which could be used for monitoring improvements in
wellbeing. On this basis, future clinical trials could be devel-
oped with appropriate screening for inclusion of significant
sub-health issues associated with fatigue, sleep and vitality.
Conclusions
Using urine excretion profiles of amino acids, it was possible
to define three major phenotypic clusters of adult human
subjects. Cluster 1 had the highest concentration of amino
acids in urine with histidine present at 2.4–3.6 times the
concentrations observed in the other clusters while cluster 2
was characterised by a high level of urinary glycine. The
three clusters thus had differential excretion characteristics
and sets of sub-health symptom profiles, where the females
within the three clusters had different associations between
nutrient losses and symptom expression compared with the
corresponding males. Evidence suggested that collagen/non-
myofibrillar muscle protein turnover rates were higher in
the females and were associated with the experience of more
intense sub-health symptom presentation compared with
the males. Provision of the amino acid supplement for
30 days resulted in significant improvements in reported
fatigue and sleep for 81% of the trial cohort. It was con-
cluded that people suffering fatigue, assessed as a Chalder
fatigue scale score > 13, would be likely to experience signifi-
cant benefits from amino acid supplementation.
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